Project for Potential Osteoarthritis Global Player

There is an opportunity to acquire US Phase 3 dosing completed asset from the original licensor and commercialize in the territories of China, Taiwan, Hong Kong, and Macau. We would like to acquire this OA asset with interested investors through a NewCo. After in-licensing, the company will develop and commercialize this late-stage OA asset further to generate revenue in Honk Kong and Taiwan first around 2029 and in China around 2030.